Intas' biosimilar Enbrel debuts at hefty discount in India
This article was originally published in Scrip
Executive Summary
Intas Pharmaceuticals has launched its cut-price etanercept, a biosimilar version of Amgen's TNF-inhibitor Enbrel, on the Indian market.